CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference
CalciMedica Inc. (Nasdaq: CALC), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's CEO, Rachel Leheny, Ph.D., will deliver a presentation on September 9, 2024, at 7:00 a.m. ET/ 4:00 a.m. PT.
CalciMedica specializes in developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. Investors and interested parties can access a live webcast of the presentation through the company's IR website. The webcast replay will be available for 90 days following the event.
CalciMedica Inc. (Nasdaq: CALC), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione alla 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. L'amministratore delegato dell'azienda, Rachel Leheny, Ph.D., terrà una presentazione il 9 settembre 2024, alle 7:00 EDT / 4:00 PDT.
CalciMedica si specializza nello sviluppo di innovative terapie di inibizione dei canali del calcio attivati dalla liberazione di calcio (CRAC) per malattie infiammatorie e immunologiche acute e croniche. Gli investitori e le parti interessate possono accedere a una diretta del webcast della presentazione tramite il sito web per gli investitori dell'azienda. La registrazione del webcast sarà disponibile per 90 giorni dopo l'evento.
CalciMedica Inc. (Nasdaq: CALC), una empresa biofarmacéutica en fase clínica, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. La CEO de la empresa, Rachel Leheny, Ph.D., realizará una presentación el 9 de septiembre de 2024, a las 7:00 a.m. ET / 4:00 a.m. PT.
CalciMedica se especializa en desarrollar terapias de inhibición de canales de calcio activados por liberación de calcio (CRAC) para enfermedades inflamatorias e inmunológicas agudas y crónicas. Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través del sitio web de IR de la empresa. La repetición de la transmisión estará disponible durante 90 días después del evento.
CalciMedica Inc. (Nasdaq: CALC), 임상 단계 바이오 제약 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO인 Rachel Leheny 박사가 2024년 9월 9일 오전 7시 ET / 오전 4시 PT에 발표를 진행할 예정입니다.
CalciMedica는 칼슘 방출 활성화 칼슘(CRAC) 채널 억제 요법을 개발하여 급성 및 만성 염증 및 면역 질환을 치료하는 데 전문화하고 있습니다. 투자자 및 관심 있는 당사자는 회사의 IR 웹사이트를 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다. 웹캐스트 재생은 이벤트 이후 90일 동안 이용할 수 있습니다.
CalciMedica Inc. (Nasdaq: CALC), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. La PDG de l'entreprise, Rachel Leheny, Ph.D., présentera le 9 septembre 2024, à 7h00 ET / 4h00 PT.
CalciMedica se spécialise dans le développement de thérapies d'inhibition des canaux de calcium activés par la libération de calcium (CRAC) pour les maladies inflammatoires et immunologiques aiguës et chroniques. Les investisseurs et parties intéressées peuvent accéder à un webcast en direct de la présentation via le site IR de l'entreprise. La rediffusion du webcast sera disponible pendant 90 jours après l'événement.
CalciMedica Inc. (Nasdaq: CALC), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright angekündigt. Die CEO des Unternehmens, Rachel Leheny, Ph.D., wird am 9. September 2024, um 7:00 Uhr ET / 4:00 Uhr PT eine Präsentation halten.
CalciMedica ist auf die Entwicklung innovativer Therapien zur Hemmung von calciumfreisetzungsaktivierten Calciumkanälen (CRAC) für akute und chronische entzündliche sowie immunologische Erkrankungen spezialisiert. Investoren und Interessierte können über die IR-Website des Unternehmens auf einen Live-Webcast der Präsentation zugreifen. Der Webcast kann 90 Tage nach der Veranstaltung wieder angesehen werden.
- None.
- None.
A live webcast of the presentation can be accessed in the "Upcoming Events" section of CalciMedica's IR website at https://ir.calcimedica.com/. A replay of the webcast will be archived on the Company's website for 90 days.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced topline data for a Phase 2b trial (called CARPO – NCT04681066) in patients with AP with SIRS and completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with AKI with associated AHRF with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in patients with AIPT with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-present-at-the-hc-wainwright-26th-annual-global-investment-conference-302234592.html
SOURCE CalciMedica, Inc.
FAQ
When is CalciMedica (CALC) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for CalciMedica (CALC) at the investment conference?
How can investors access CalciMedica's (CALC) presentation at the conference?
What is the focus of CalciMedica's (CALC) research and development?
How long will the replay of CalciMedica's (CALC) presentation be available?
